The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization among infants, and is the cause of considerable morbidity in the Artic regions. Although a safe and effective RSV vaccine remains elusive, palivizumab has shown considerable promise as a prophylactic agent in previou...

Full description

Bibliographic Details
Main Authors: Banerji, Anna, Panzov, Vladimir, Young, Michael, Lee, Bonita E, Mamdani, Muhammad, Giles, B Louise, Dennis, Marguerite, Morel, Johanne, Bisson, Danny, Paes, Bosco A, Hui, Charles, Mahony, Jim
Format: Text
Language:English
Published: Pulsus Group Inc 2014
Subjects:
Original Article
Nunavut
inuit
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128465
http://www.ncbi.nlm.nih.gov/pubmed/24367792
Description
Summary:Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization among infants, and is the cause of considerable morbidity in the Artic regions. Although a safe and effective RSV vaccine remains elusive, palivizumab has shown considerable promise as a prophylactic agent in previous randomized controlled trials. Prompted by the lack of published data involving Inuit or Aboriginal infants, this prospective, observational study aimed to estimate the effectiveness of palivizumab against RSV in this population.

Similar Items